510(k) Report

510(k) · Cleared

Cleared

N-Assay CPK-L

K980900510(k) TraditionalCleared Mar 26, 199816-day reviewClass II21 CFR 862.1215

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Crestat Diagnostics, Inc. · CGS Nad Reduction/Nadh Oxidation, Cpk Or Isoenzymes

Cleared on Mar 26, 1998 as substantially equivalent to K781719 (Medical Analysis Systems, Inc., 1978) after a 16-day review. Its family tree reaches back 1 generation to 1978.

Decided
Mar 26, 1998
Review
16 days
Class
Class II
Product code
CGS
Recalls
None
Predicates
1

Its longest line of descent runs back 1 generation to K781719 (1978). No later device cites it as a predicate yet.

K781719 · CPK Reagent Set, Nad Reduction · Medical Analysis Systems, Inc. · 1978197519801985199019952000
  1. Root · 1 generation backK781719 CPK Reagent Set, Nad ReductionMedical Analysis Systems, Inc. · 1978
  2. This deviceK980900 N-Assay CPK-LCrestat Diagnostics, Inc. · 1998
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−1K781719CPK Reagent Set, Nad ReductionMedical Analysis Systems, Inc.1978—
0 (this device)K980900N-Assay CPK-LCrestat Diagnostics, Inc.1998—
FIG. 1 — Lineage of K980900, 1978–1998Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in CGS? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new CGS device

  1. #1 K191296 Pointe Scientific Creatinine Kinase (CK)…score -0.2 · 1 generation · no Class I recall
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K781719CPK Reagent Set, Nad Reduction
Summary page 2
…he safety and effectiveness of the liquid Crestat N-ASSAY CPK-L Reagent is demonstrated by its substantial equivalence to the Medical Analysis Systems CK liquid reagent (K781719) which is based on a similar method. Both test systems are intended to quantitatively measure CPK in human serum. In comparison…
Medical Analysis Systems, Inc.1978—

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • Its one ancestor has no recall.

How does its category compare?

All CGS devices

CGS Nad Reduction/Nadh Oxidation, Cpk Or Isoenzymes: FDA decisions, review times, recalls and adverse event reports over 20 years.

FDA decisions per year · CGS

1in 2020

2007: 12008: 22009: 12011: 12013: 12016: 12019: 12020: 1
2007high 2 (2008) · low 0 (2010)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · CGS

Too few CGS 510(k)s in any year since 2007 to give a median.

Recalls per year · CGS

1in 2025

2007: 12025: 1
2007high 1 (2007) · low 0 (2008)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · CGS

2in 2025

2007: 642010: 12011: 32017: 22018: 1,4342019: 42022: 12024: 12025: 2
2007high 1,434 (2018) · low 0 (2008)2025

MAUDE reports naming product code CGS, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20071—164
20082—00
20091—00
20100—01
20111—03
20120—00
20131—00
20140—00
20150—00
20161—00
20170—02
20180—01,434
20191—04
20201—00
20210—00
20220—01
20230—00
20240—01
20250—12
20260—0—

What is it indicated for?

The intended use for the N-ASSAY CPK-L Reagent is for the quantitative determination of serum creatine phosphokinase (CPK) activity in human serum in the diagnosis and treatment of myocardial infarction and muscle diseases such as muscular dystrophy.

Indications for use read by OCR from a scanned FDA summary, so letters may be misread. Check the PDF before quoting it.

Cite this page

510(k) Report. “K980900: N-Assay CPK-L.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 4, 2026. https://510kreport.com/device/K980900

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026